In last trading session, Biohaven Ltd (NYSE:BHVN) saw 0.53 million shares changing hands with its beta currently measuring 3.86. Company’s recent per share price level of $46.06 trading at -$0.32 or -0.69% at ring of the bell on the day assigns it a market valuation of $4.66B. That closing price of BHVN’s stock is at a discount of -35.06% from its 52-week high price of $62.21 and is indicating a premium of 41.82% from its 52-week low price of $26.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.97 million shares which gives us an average trading volume of 1.02 million if we extend that period to 3-months.
For Biohaven Ltd (BHVN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.13. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.72 in the current quarter.
Biohaven Ltd (NYSE:BHVN) trade information
Upright in the red during last session for losing -0.69%, in the last five days BHVN remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $46.06 price level, adding 3.54% to its value on the day. Biohaven Ltd’s shares saw a change of 7.62% in year-to-date performance and have moved 1.93% in past 5-day. Biohaven Ltd (NYSE:BHVN) showed a performance of -8.72% in past 30-days. Number of shares sold short was 7.82 million shares which calculate 10.3 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 59 to the stock, which implies a rise of 21.93% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 68. It follows that stock’s current price would jump 50.07% in reaching the projected high whereas dropping to the targeted low would mean a gain of 50.07% for stock’s current value.
Biohaven Ltd (BHVN) estimates and forecasts
Statistics highlight that Biohaven Ltd is scoring comparatively lower than the scores of other players of the relevant industry. The company added 31.23% of value to its shares in past 6 months, showing an annual growth rate of -54.45% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.09M for the same. And 5 analysts are in estimates of company making revenue of 2.5M in the next quarter.
Biohaven Ltd (NYSE:BHVN)’s Major holders
Insiders are in possession of 11.16% of company’s total shares while institution are holding 86.77 percent of that, with stock having share float percentage of 97.67%. Investors also watch the number of corporate investors in a company very closely, which is 86.77% institutions for Biohaven Ltd that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BHVN for having 7.27 million shares of worth $252.41 million. And as of 2024-06-30, it was holding 8.9114 of the company’s outstanding shares.
The second largest institutional holder is STIFEL FINANCIAL CORP, which was holding about 6.48 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9417 of outstanding shares, having a total worth of $224.94 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 2.2 shares of worth $101.2 million or 2.18% of the total outstanding shares. The later fund manager was in possession of 2.02 shares on Aug 31, 2024 , making its stake of worth around $93.14 million in the company or a holder of 2.00% of company’s stock.
